Updated from 1:49 p.m. EDTWidely held health care stocks were mixed Wednesday, with Bristol-Myers Squibb ( BMY - Get Report) slipping on an analyst downgrade and earnings reports from two drugmakers. Goldman Sachs downgraded Bristol from Buy to Neutral on Wednesday, citing relative valuation and the company's diminishing chances of getting taken over. Shares were recently down 2.6% to $19.14. After falling earlier in the day, Pfizer ( PFE - Get Report) was recently up 0.8% to $13.50, and Johnson & Johnson ( JNJ - Get Report) was up 0.4% to $50.83. Wyeth ( WYE) was rising after the company reported flat first-quarter earnings, blaming a strong U.S. dollar and sluggish sales of Effexor, a breadwinner for the company. Shares of the company were rising 0.1% to $42.73 in recent trading. Sanofi-Aventis ( SNY - Get Report) was on the rise after the company announced it was halting work on three late-stage trial drugs. The company also reported a 19% increase in net profit for the first quarter of fiscal 2009. Also potentially lifting the stock, the company announced it had been contacted by health officials regarding the development and production of a vaccine to help prevent the spread of swine flu. Sanofi-Aventis shares were recently up 5.8% to $28.74. Among other widely held health care stocks: Eli Lilly ( LLY) was up 0.5% to $33.38. Merck ( MRK - Get Report) was up 3.5% to $23.99. GlaxoSmithKline ( GSK - Get Report) was up 2.4% to $30.89.
More from Stocks
Amazon Prime Day Sales Topped $7 Billion: Internet Retailer
An early analysis by Internet Retailer estimates that Amazon's 48-hour Prime Day event hit $7.16 billion in sales, surpassing an earlier estimate of more than $6 billion.
Combative Hearings for Facebook's Libra Suggest Project Could Face Long Delays
After the contentious series of hearings, Rep. Maxine Waters and others said that Facebook CEO Mark Zuckerberg should be called to testify on plans for the cryptocurrency.
The 3 Things Jim Cramer Must See Before He'll Buy An Expensive Stock
Anything with a high P/E must have a large total addressable market, the ability to scale up its business and a wide 'moat.' One stock that fits the bill: Mastercard.
Jim Cramer: The 'Secret Sauce' Behind Mastercard's Stock
Curious about Mastercard's stock and how the company is so successful? Here's what Jim Cramer has to say about the company.